Graham Capital Management’s Pacific Biosciences PACB Stock Holding History

Graham Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,179	Closed	-$55.7K	–	1436
2026 Q1	$55.7K	Sell	42,179 -146,306	-78%	-$262K	﹤0.01%	1087
2025 Q4	$352K	Buy	+188,485	New	+$362K	0.01%	784
2022 Q3	–	Sell	-134,862	Closed	-$596K	–	1249
2022 Q2	$596K	Buy	+134,862	New	+$819K	0.02%	612
2022 Q1	–	Sell	-16,475	Closed	-$337K	–	993
2021 Q4	$337K	Sell	16,475 -15,000	-48%	-$362K	0.01%	278
2021 Q3	$804K	Sell	31,475 -8,419	-21%	-$249K	0.04%	98
2021 Q2	$1.4M	Sell	39,894 -4,982	-11%	-$145K	0.07%	103
2021 Q1	$1.49M	Buy	+44,876	New	+$1.57M	0.07%	119

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Graham Capital Management's PACB Position: Q2 2026 in Review

Graham Capital Management sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 42,179 shares — an estimated $55.7K sold.

Graham Capital Management first reported a position in PACB in Q1 2021 and held it in 7 quarters. The position peaked at $1.49M in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Graham Capital Management reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
Graham Capital Management sold 42,179 Pacific Biosciences shares in Q2 2026, an estimated $55.7K.
Graham Capital Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 7 quarters.
Graham Capital Management's Pacific Biosciences position peaked at $1.49M in Q1 2021.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.